Results 301 to 310 of about 332,782 (345)
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Immunotherapy, 2017 [[abstract]]Cancer immunotherapy is a growing field. GM-CSF, a potent cytokine promoting the differentiation of myeloid cells, can also be used as an immunostimulatory adjuvant to elicit antitumor immunity.
Kuan-Yin Shen, Shih-Jen Liu
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The role of GM-CSF in infection
Infection, 1992GM-CSF is a hemopoietic growth factor with substantial effects on the proliferation of neutrophils, eosinophils and monocytes/macrophages. Its physiologic role in infection is still poorly understood. The gene for GM-CSF is constitutively transcribed in cells substantial for antiinfectious response. Various cells are activated and induced by TNF and IL-
M, Freund, H D, Kleine
openaire +2 more sources
Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation
Clinical Immunology, 2001We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425--500 ...
G, Ullenhag +8 more
openaire +2 more sources
GM-CSF in marrow transplantation
European Journal of Cancer, 1993Bone marrow transplantation (BMT) is being increasingly used in a wide variety of diseases. During the period of re-engraftment the patient is particularly susceptible to a number of opportunistic infections which can radically affect acute morbidity and mortality.
openaire +2 more sources
Infection, 1992
Hematopoietic growth factors may mitigate the cytopenias that frequently complicate HIV disease or its treatment. Clinical and in vitro studies have indicated the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) or erythropoietin (EPO) to overcome the myelosuppression of HIV or many of ...
openaire +2 more sources
Hematopoietic growth factors may mitigate the cytopenias that frequently complicate HIV disease or its treatment. Clinical and in vitro studies have indicated the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) or erythropoietin (EPO) to overcome the myelosuppression of HIV or many of ...
openaire +2 more sources
GM‐CSF and phorbol esters modulate GM‐CSF receptor expression by independent mechanisms
Journal of Cellular Physiology, 1991AbstractHuman granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) (0.1 nM) down‐modulates its receptor in IL‐3/GM‐CSF dependent M‐07e cells, in KG‐1 cells and normal granulocytes, whereas phorbol esters 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) (2 nM) down‐modulates the GM‐CSF receptor in M‐07e cells and granulocytes but not in KG‐1 cells.
BRIZZI M. F +4 more
openaire +2 more sources
Targeting GM-CSF in inflammatory diseases
Nature Reviews Rheumatology, 2015Granulocyte-macrophage colony stimulating factor (GM-CSF) is a growth factor first identified as an inducer of differentiation and proliferation of granulocytes and macrophages derived from haematopoietic progenitor cells. Later studies have shown that GM-CSF is involved in a wide range of biological processes in both innate and adaptive immunity, with
Ian P, Wicks, Andrew W, Roberts
openaire +2 more sources
GM‐CSF in the treatment of Felty syndrome
American Journal of Hematology, 1991AbstractMany therapeutic agents have been tried with variable success in the treatment of Felty neutropenia, but the reports are anecdotal. We now describe the second trial of recombinant granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), in a splenectomized, infected patient with Felty syndrome.
G, Joseph +4 more
openaire +2 more sources
GM‐CSF in the treatment of Fanconi's anaemia
British Journal of Haematology, 1994SummaryWe have used recombinant human (rh) GM‐CSF in two 12‐year‐old Fanconi's aplastic anaemia patients. They had not received any previous therapy except blood transfusions. Each patient was given three 21 d courses of rh‐GM‐CSF, the first two at a dose of 3.5μg/kg/d and the third at 7 μg/kg/d s.c. There were significant increases in WBC and absolute
S, Kemahli +5 more
openaire +2 more sources